Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CCNC | P24863 | 2/20 | 0.58 |
| ▸ | CDK8 | P49336 | 2/20 | 0.58 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.58 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.58 |
| ▸ | CDK1 | P06493 | 2/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19117833 | 0.84 | CCNC (0.66) | IRAK4CYP1A2CYP3A4CLK4ALDH1A1 | |
| SCHEMBL22549000 | 0.78 | IRAK4 (0.50) | IRAK4CYP1A2CYP3A4CLK4ALDH1A1 | |
| SCHEMBL23806243 | 0.77 | IRAK4 (0.81) | IRAK4 | |
| SCHEMBL23945170 | 0.77 | IRAK4 (0.81) | IRAK4 | |
| SCHEMBL8297788 | 0.76 | HTT (0.64) | IRAK4CYP1A2CYP3A4CLK4ALDH1A1 | |
| SCHEMBL2622072 | 0.76 | HTT (0.68) | IRAK4CYP1A2CYP3A4CLK4ALDH1A1 | |
| SCHEMBL19179644 | 0.76 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL5764429 | 0.76 | LMNA (0.78) | CYP1A2CYP3A4CLK4ALDH1A1MAPK1 | |
| SCHEMBL19179518 | 0.76 | IRAK4 (1.00) | IRAK4 | |
| SCHEMBL17209399 | 0.76 | IRAK4 (0.81) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885CYP1A2 3570/4885CYP3A4 2542/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885CYP1A2 3570/4885CYP3A4 2542/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885CYP1A2 3570/4885CYP3A4 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.